DuPont Applied BioSciences is collaborating with MBI International to commercialization a new bio-based product line.
According to excerpts from the article:
MBI International is a leader in bridging the gap between research and commercialization through collaborative de-risking of bio-based technologies. MBI's unique "Collaborative De-Risking"process systematically addresses technological uncertainties, which impede new technologies from getting to market.
"We are very excited that DuPont Applied BioSciences has chosen MBI as a partner to help de-risk this important new product line," stated Dr. Bobby Bringi, recently appointed President of MBI International. "We had the opportunity to work with DuPont Applied BioSciences on an initial phase of this project, and are proud that they have chosen to extend this partnership with MBI."
MBI International fits a unique niche in the marketplace. Virtually all bio-based technology developments that come from the lab need to go through a process development and scale-up stage to determine commercial viability. Once the uncertainties or risks associated with early technological developments are mitigated via de-risking, a company like DuPont Applied BioSciences is better positioned to make product-related investments.
Read the entire article here.
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.